Nemesis Bioscience receives Innovate UK smart funding award for development of its novel therapeutic delivery method
Nemesis Bioscience Ltd (Cambridge, UK) announced today that it
has received a funding award from the UK’s innovation agency,
Innovate UK. The Smart Award will be used to develop and protect a
novel method for the delivery of polynucleotides, including
therapeutics, into bacteria.
Nemesis Bioscience Ltd has invented, developed and protected a
family of novel biological therapeutic agents that inactivate
resistance to antibiotics, so allowing well-established safe
generic antibiotics to be effective again. The company has proven
in the laboratory that its “Nemesis Symbiotics convert
antimicrobial resistant (AMR) bacteria to antibiotic sensitivity
and also prevent bacteria from acquiring AMR – opening the
possibility of protecting patients pre-operatively, or even
pre-admission, to lower the risks of subsequent AMR infection.
To date, delivery systems into target bacteria have been
developed for these Nemesis Symbiotics using different vehicles
for either treatment or protection. A single delivery method for
both treatment and protection in a clinical setting is essential
for clinical utility and economic feasibility.
The company has now invented such a delivery mechanism –
Transmids that can be used clinically in the main focus areas of
overcoming and preventing AMR without needing separate delivery
mechanisms. However, the unique properties of Transmids also may
make them ideal for use in existing synthetic biology and
industrial microbiology applications where manipulation of
bacterial genetics is fundamental – for example, the microbial
production of biochemicals, biofuels and therapeutics.
The CEO of Nemesis, Dr Frank Massam commented, “This Smart Award
will help us to efficiently evaluate and develop our new Transmid
technology not only for the clinical delivery of our range of
therapeutics but also for economically important synthetic biology